ZIVO Stock Overview
A research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ZIVO Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.10 |
| 52 Week High | US$22.15 |
| 52 Week Low | US$1.20 |
| Beta | 0.16 |
| 1 Month Change | 5.79% |
| 3 Month Change | 26.65% |
| 1 Year Change | 1,580.61% |
| 3 Year Change | 26.58% |
| 5 Year Change | -72.10% |
| Change since IPO | -98.58% |
Recent News & Updates
Shareholder Returns
| ZIVO | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 10.5% | -4.7% | -2.2% |
| 1Y | 1,580.6% | -24.7% | 23.9% |
Return vs Industry: ZIVO exceeded the US Personal Products industry which returned -24.7% over the past year.
Return vs Market: ZIVO exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| ZIVO volatility | |
|---|---|
| ZIVO Average Weekly Movement | 14.8% |
| Personal Products Industry Average Movement | 8.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZIVO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ZIVO's weekly volatility has decreased from 27% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | John Payne | www.zivobioscience.com |
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging.
ZIVO Bioscience, Inc. Fundamentals Summary
| ZIVO fundamental statistics | |
|---|---|
| Market cap | US$67.38m |
| Earnings (TTM) | -US$13.69m |
| Revenue (TTM) | US$79.02k |
991.8x
P/S Ratio-5.7x
P/E RatioIs ZIVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZIVO income statement (TTM) | |
|---|---|
| Revenue | US$79.02k |
| Cost of Revenue | US$52.94k |
| Gross Profit | US$26.08k |
| Other Expenses | US$13.72m |
| Earnings | -US$13.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.86 |
| Gross Margin | 33.01% |
| Net Profit Margin | -17,327.26% |
| Debt/Equity Ratio | -17.0% |
How did ZIVO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 09:41 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ZIVO Bioscience, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anthony Vendetti | Maxim Group |